guly
Forumer storico
lascia perdere.materia obsoleta.ormai ci sono altri materiali che domineranno il futuro.pre me il grafene o grafite e' ormai un materiale superato.poi fai tu.a me non interessa.meglio le nanotecnologie o la biogenetica.
NicOx.... in attesa di..... (2 lettori)
- Creatore Discussione DickSIM
- Data di Inizio
guly
Forumer storico
troppi sogni.nicox e' stato solo un delirio per molti.bisognava vendere a 24.io putroppo mi feci condizionare da alcuni pagliacci che sparavano mirabilie,razzi e frizzi.li ammetto sono stato un cretino.me lo ripeto spesso.poi per fortuna,anche se un po' troppo tardi,sono tornato in me e ho fatto la mossa giusta.e' stata una dura lezione.mai piu' credere a buffoni e affabulatori che sparano mirabilie e enfatizzano i titoli.mai piu'.
PIZZODIGINO
Pacifico
In base a cosa dici che è materia obsoleta ?
Guarda che il grafene è ancora in fase di sviluppo, quindi non può essere obsoleto; forse ti sbagli con qualche altro materiale.
PIZZODIGINO
Pacifico
Forse sono solo un povero illuso, ma io a Garufi credo ancora e pertanto sin che lui non molla, non mollo nemmeno io.
Poi so benissimo che non dipende solo dalla sua volontà che le cose vadano bene, ma sono i medicinali che devono funzionare.
Ora il No-Xalatan sembra davvero messo sulla buona strada e Bausch + Lomb - Valiant sono una garanzia di serietà.
Vedremo cosa succederà a fine anno con gli esiti della fase III e a inizio 2015 con la decisione del grosso fondo Europeo in merito al Naproxcinod-Duchenne.
L'ottimismo l'ho ormai quasi perso tutto, ma mi rimane ancora una certa speranza di rivedere dei prezzi dell'azione decorosi.
Poi so benissimo che non dipende solo dalla sua volontà che le cose vadano bene, ma sono i medicinali che devono funzionare.
Ora il No-Xalatan sembra davvero messo sulla buona strada e Bausch + Lomb - Valiant sono una garanzia di serietà.
Vedremo cosa succederà a fine anno con gli esiti della fase III e a inizio 2015 con la decisione del grosso fondo Europeo in merito al Naproxcinod-Duchenne.
L'ottimismo l'ho ormai quasi perso tutto, ma mi rimane ancora una certa speranza di rivedere dei prezzi dell'azione decorosi.
Zohar
Forumer storico
Il pizzettaro partenopeo non ha MAI dato comprova di affidabilità e capacità in termini di approvazione di farmaci ...
Direi molto il contrario ... spifferi di aria gelida che hanno solo fornito dei gran mal di testa e torcicollo ...
Per non parlare poi dei risultati della "managerialità" ... oltre 150 dipendenti ... ossia un gran carrozzone di super dirigenti ed esperti , con risultati da chiosco di gelati.
I miei complimenti al "Gran Condottiero"
Ultima modifica:
PIZZODIGINO
Pacifico
Un saluto a chi ci crede ancora. Io su nicox ci sono ancora :-( Meno male che nel mio portafoglio c'è anche Pharming group.
Ecco cosa può succedere alla vigilia dell'approvazione di un farmaco. Nervi saldi!
Ciao Aeiou, speriamo che Nicox ci dia qualche soddisfazione, perché i nervi ormai sono quasi esauriti.
Bye
PIZZODIGINO
Pacifico
Il pizzettaro partenopeo non ha MAI dato comprova di affidabilità e capacità in termini di approvazione di farmaci ...
Direi molto il contrario ... spifferi di aria gelida che hanno solo fornito dei gran mal di testa e torcicollo ...
Per non parlare poi dei risultati della "managerialità" ... oltre 150 dipendenti ... ossia un gran carrozzone di super dirigenti ed esperti , con risultati da chiosco di gelati.
I miei complimenti al "Gran Condottiero"
Aspetta a condannarlo, non ha ancora finito la sua opera; solo alla fine potremo dare un giudizio definitivo.
PIZZODIGINO
Pacifico
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Aciex Therapeutics, Inc.
Sponsor:
Aciex Therapeutics, Inc.
Information provided by (Responsible Party):
Aciex Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02132169
First received: April 29, 2014
Last updated: May 5, 2014
Last verified: May 2014
History of Changes
Full Text View
Tabular View
No Study Results Posted
Disclaimer
How to Read a Study Record
Purpose The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).
Study Type: Interventional Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment Official Title: A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)
Resource links provided by NLM:
MedlinePlus related topics: Pinkeye
U.S. FDA Resources
Further study details as provided by Aciex Therapeutics, Inc.:
Primary Outcome Measures: Tolerability of AC 170 0.24% compared to its vehicle [ Time Frame: up to 12 weeks ] [ Designated as safety issue: No ] Tolerability of AC 170 0.024% compared to its vehicle will be measured at Visit 1-3. Subjects will assess their comfort based on an approved scale.
Secondary Outcome Measures: Safety of AC 170 0.024% compared to its vehicle [ Time Frame: Up to 12 Weeks ] [ Designated as safety issue: No ] Safety measures (adverse events, etc.) of AC 170 0.024% compared to its vehicle will be measured at Visit 1-4 and 5 (for subset of patients).
Estimated Enrollment: 501 Study Start Date: May 2014 Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Eligibility
Ages Eligible for Study: 2 Years and older Genders Eligible for Study: Both Accepts Healthy Volunteers: No Criteria
Inclusion Criteria:
at least 2 years of age
be able to self-administer eye drops or have a parent/legal guardian available for this purpose
if less than 18 years old have a history or family history of atopic disease (including allergic conjunctivitis)
have ocular health within normal limits
Exclusion Criteria:
known contraindications or sensitivities to the study medication or its components
any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
use of disallowed medication during the period indicated prior to the enrollment or during the study
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02132169
Contacts
Contact: Tom Cavanagh 917-969-9339 [email protected]
Locations
United States, Massachusetts Andover Eye Associates Recruiting Andover, Massachusetts, United States, 01810 Contact: Allie Griffin 978-685-8900 Sponsors and Collaborators
Aciex Therapeutics, Inc.
More Information
No publications provided
This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Aciex Therapeutics, Inc.
Sponsor:
Aciex Therapeutics, Inc.
Information provided by (Responsible Party):
Aciex Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02132169
First received: April 29, 2014
Last updated: May 5, 2014
Last verified: May 2014
History of Changes
Full Text View
Tabular View
No Study Results Posted
Disclaimer
How to Read a Study Record
Condition Intervention Phase Atopc Disease (Including Allergic Conjunctivitis)
Drug: Drug: AC-170 0.24%
Drug: AC-170 0%
Phase 3
Drug: Drug: AC-170 0.24%
Drug: AC-170 0%
Phase 3
Study Type: Interventional Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment Official Title: A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)
Resource links provided by NLM:
MedlinePlus related topics: Pinkeye
U.S. FDA Resources
Further study details as provided by Aciex Therapeutics, Inc.:
Primary Outcome Measures: Tolerability of AC 170 0.24% compared to its vehicle [ Time Frame: up to 12 weeks ] [ Designated as safety issue: No ] Tolerability of AC 170 0.024% compared to its vehicle will be measured at Visit 1-3. Subjects will assess their comfort based on an approved scale.
Secondary Outcome Measures: Safety of AC 170 0.024% compared to its vehicle [ Time Frame: Up to 12 Weeks ] [ Designated as safety issue: No ] Safety measures (adverse events, etc.) of AC 170 0.024% compared to its vehicle will be measured at Visit 1-4 and 5 (for subset of patients).
Estimated Enrollment: 501 Study Start Date: May 2014 Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions Experimental: AC-170 0.24% Drug: Drug: AC-170 0.24% Other Name: 1 drop in each eye 2 times daily for up to 6 weeks
Placebo Comparator: AC-170 0% Drug: AC-170 0% Other Name: 1 drop in each eye 2 times daily for up to 6 weeks
Placebo Comparator: AC-170 0% Drug: AC-170 0% Other Name: 1 drop in each eye 2 times daily for up to 6 weeks
Ages Eligible for Study: 2 Years and older Genders Eligible for Study: Both Accepts Healthy Volunteers: No Criteria
Inclusion Criteria:
at least 2 years of age
be able to self-administer eye drops or have a parent/legal guardian available for this purpose
if less than 18 years old have a history or family history of atopic disease (including allergic conjunctivitis)
have ocular health within normal limits
Exclusion Criteria:
known contraindications or sensitivities to the study medication or its components
any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
use of disallowed medication during the period indicated prior to the enrollment or during the study
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02132169
Contacts
Contact: Tom Cavanagh 917-969-9339 [email protected]
Locations
United States, Massachusetts Andover Eye Associates Recruiting Andover, Massachusetts, United States, 01810 Contact: Allie Griffin 978-685-8900 Sponsors and Collaborators
Aciex Therapeutics, Inc.
No publications provided
PIZZODIGINO
Pacifico
A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%
This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Aciex Therapeutics, Inc.
Sponsor:
Aciex Therapeutics, Inc.
Information provided by (Responsible Party):
Aciex Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02173249
First received: June 13, 2014
Last updated: June 23, 2014
Last verified: June 2014
History of Changes
Full Text View
Tabular View
No Study Results Posted
Disclaimer
How to Read a Study Record
Purpose The purpose of this study is to evaluate the Plasma Pharmacokinetics and Safety of AC 170 0.24% in Healthy, Adult Subjects when used twice daily for one week.
Study Type: Interventional Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Further study details as provided by Aciex Therapeutics, Inc.:
Primary Outcome Measures: <LI class=color-bullet style="MARGIN-TOP: 0.7ex">Cmax values of AC 170 0.24% [ Time Frame: 1 week ] [ Designated as safety issue: No ] Plasma samples will be drawn at specified time points and then analyzed to determine Cmax values of AC 170 0.24% in the plasma
<LI class=color-bullet style="MARGIN-TOP: 0.7ex">Tmax values of AC 170 0.24% [ Time Frame: 1 week ] [ Designated as safety issue: No ] Plasma samples will be drawn at specified time points and then analyzed to determine Tmax values of AC 170 0.24% in the plasma
<LI class=color-bullet style="MARGIN-TOP: 0.7ex">AUC values of AC 170 0324% [ Time Frame: 1 week ] [ Designated as safety issue: No ] Plasma samples will be drawn at specified time points and then analyzed to determine AUC values of AC 170 0.24% in the plasma
T 1/2 values of AC 170 0.24% [ Time Frame: 1 week ] [ Designated as safety issue: No ] Plasma samples will be drawn at specified time points and then analyzed to determine T 1/2 values of AC 170 0.24% in the plasma
Estimated Enrollment: 15 Study Start Date: June 2014 Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Eligibility
Ages Eligible for Study: 18 Years to 55 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No Criteria
Inclusion Criteria:
at least 18 and no older than 55 years of age
be able to self-administer eye drops or have a parent/legal guardian available for this purpose
have blood and urine analysis within normal limits
have ocular health within normal limits
Exclusion Criteria:
known contraindications or sensitivities to the study medication or its components
have any active systemic or ocular disorder (other than refractive disorder)
have inability to comply with controlled diet
have used prescription or non prescription drugs within washout period and throughout study
have used alcohol or tobacco within the washout period
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02173249
Locations
United States, Massachusetts Andover Eye Associates Recruiting Andover, Massachusetts, United States, 01810 Contact: Allie Griffin 978-685-8900 Sponsors and Collaborators
Aciex Therapeutics, Inc.
This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Aciex Therapeutics, Inc.
Sponsor:
Aciex Therapeutics, Inc.
Information provided by (Responsible Party):
Aciex Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02173249
First received: June 13, 2014
Last updated: June 23, 2014
Last verified: June 2014
History of Changes
Full Text View
Tabular View
No Study Results Posted
Disclaimer
How to Read a Study Record
Study Type: Interventional Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Further study details as provided by Aciex Therapeutics, Inc.:
Primary Outcome Measures: <LI class=color-bullet style="MARGIN-TOP: 0.7ex">Cmax values of AC 170 0.24% [ Time Frame: 1 week ] [ Designated as safety issue: No ] Plasma samples will be drawn at specified time points and then analyzed to determine Cmax values of AC 170 0.24% in the plasma
<LI class=color-bullet style="MARGIN-TOP: 0.7ex">Tmax values of AC 170 0.24% [ Time Frame: 1 week ] [ Designated as safety issue: No ] Plasma samples will be drawn at specified time points and then analyzed to determine Tmax values of AC 170 0.24% in the plasma
<LI class=color-bullet style="MARGIN-TOP: 0.7ex">AUC values of AC 170 0324% [ Time Frame: 1 week ] [ Designated as safety issue: No ] Plasma samples will be drawn at specified time points and then analyzed to determine AUC values of AC 170 0.24% in the plasma
T 1/2 values of AC 170 0.24% [ Time Frame: 1 week ] [ Designated as safety issue: No ] Plasma samples will be drawn at specified time points and then analyzed to determine T 1/2 values of AC 170 0.24% in the plasma
Estimated Enrollment: 15 Study Start Date: June 2014 Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions Experimental: AC 170 0.24% Drug: AC 170 0.24% 1 drop in each eye 2 times daily for 1 week
Ages Eligible for Study: 18 Years to 55 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No Criteria
Inclusion Criteria:
at least 18 and no older than 55 years of age
be able to self-administer eye drops or have a parent/legal guardian available for this purpose
have blood and urine analysis within normal limits
have ocular health within normal limits
Exclusion Criteria:
known contraindications or sensitivities to the study medication or its components
have any active systemic or ocular disorder (other than refractive disorder)
have inability to comply with controlled diet
have used prescription or non prescription drugs within washout period and throughout study
have used alcohol or tobacco within the washout period
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02173249
Locations
United States, Massachusetts Andover Eye Associates Recruiting Andover, Massachusetts, United States, 01810 Contact: Allie Griffin 978-685-8900 Sponsors and Collaborators
Aciex Therapeutics, Inc.